Research programme: microRNA 7-based therapeutics - MiReven

Drug Profile

Research programme: microRNA 7-based therapeutics - MiReven

Alternative Names: miR-7 cancer therapeutics - MiReven Pty; miR-7 mimetics - MiReven/Silence Therapeutics; miR-7-5p

Latest Information Update: 25 Jul 2016

Price : $50

At a glance

  • Originator MiReven
  • Class MicroRNAs
  • Mechanism of Action Epidermal growth factor receptor antagonists; Insulin receptor substrate protein modulators; MicroRNA stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer; Head and neck cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in Australia
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Head-and-neck-cancer in Australia
  • 12 Feb 2013 Pharmacodynamics data from a preclinical trial in Cancer released by MiReven
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top